Short course of ART during primary HIV infection has immunological and virological benefits after treatment is stopped
Starting antiretroviral therapy significantly reduces the risk of decompensated liver disease for men with HIV/HCV co-infection
Severity of HIV seroconversion illness associated with subsequent disease progression
Proportion of people in southern Africa starting ART with advanced HIV disease falls
Progress towards an HIV cure
Systematic review and meta-analysis shows equivalence of 3TC and FTC
Dolutegravir matches or surpasses other regimens for first-line HIV treatment
Late testing rates declining in Europe, but largely in gay men
Dual therapy with Kaletra and 3TC works well regardless of viral load
